CONTEXT: Bevacizumab (BEV) is a monoclonal antibody to vascular endothelial growth factor (VEGF) that ameliorates atheroma progression by inhibiting neovascularization. OBJECTIVE: We aimed to determine whether BEV release from echogenic liposomes (BEV-ELIP) could be enhanced by color Doppler ultrasound (US) and whether the released BEV inhibits VEGF expression by endothelial cells in vitro. MATERIALS AND METHODS: BEV-ELIP samples were subjected to 6 MHz color Doppler ultrasound (MI = 0.4) for 5 min. We assessed release of BEV with a direct ELISA and with fluoresceinated BEV (FITC-BEV) loaded into ELIP by the same method. Human umbilical vein endothelial cell (HUVEC) cultures were stimulated to express VEGF by 10 nM phorbol-12-myristate 13-acetate (PMA). Cell-associated VEGF levels were determined using a cell-based ELISA. RESULTS: Overall, US caused an additional 100 µg of BEV to be released or exposed per BEV-ELIP aliquot within 60 min BEV-ELIP treated with US inhibited VEGF expression by 90% relative to non-treated controls and by 70% relative to BEV-ELIP without US. Also, US-treated BEV-ELIP inhibited HUVEC proliferation by 64% relative to untreated controls and by 45% relative to BEV-ELIP without US. DISCUSSION AND CONCLUSION: We have demonstrated that BEV-ELIP retains its VEGF-binding activity in a liposomal formulation and that clinical Doppler US can significantly increase that activity, both by releasing free BEV and by enhancing the surface exposure of the immunoreactive antibody.
CONTEXT: Bevacizumab (BEV) is a monoclonal antibody to vascular endothelial growth factor (VEGF) that ameliorates atheroma progression by inhibiting neovascularization. OBJECTIVE: We aimed to determine whether BEV release from echogenic liposomes (BEV-ELIP) could be enhanced by color Doppler ultrasound (US) and whether the released BEV inhibits VEGF expression by endothelial cells in vitro. MATERIALS AND METHODS:BEV-ELIP samples were subjected to 6 MHz color Doppler ultrasound (MI = 0.4) for 5 min. We assessed release of BEV with a direct ELISA and with fluoresceinated BEV (FITC-BEV) loaded into ELIP by the same method. Human umbilical vein endothelial cell (HUVEC) cultures were stimulated to express VEGF by 10 nM phorbol-12-myristate 13-acetate (PMA). Cell-associated VEGF levels were determined using a cell-based ELISA. RESULTS: Overall, US caused an additional 100 µg of BEV to be released or exposed per BEV-ELIP aliquot within 60 min BEV-ELIP treated with US inhibited VEGF expression by 90% relative to non-treated controls and by 70% relative to BEV-ELIP without US. Also, US-treated BEV-ELIP inhibited HUVEC proliferation by 64% relative to untreated controls and by 45% relative to BEV-ELIP without US. DISCUSSION AND CONCLUSION: We have demonstrated that BEV-ELIP retains its VEGF-binding activity in a liposomal formulation and that clinical Doppler US can significantly increase that activity, both by releasing free BEV and by enhancing the surface exposure of the immunoreactive antibody.
Entities:
Keywords:
Controlled release/delivery; in vitro models; nanotechnology; therapeutic antibodies
Authors: Susan D Tiukinhoy; Amer A Khan; Shaoling Huang; Melvin E Klegerman; Robert C MacDonald; David D McPherson Journal: Invest Radiol Date: 2004-02 Impact factor: 6.016
Authors: J Herrmann; L O Lerman; M Rodriguez-Porcel; D R Holmes; D M Richardson; E L Ritman; A Lerman Journal: Cardiovasc Res Date: 2001-09 Impact factor: 10.787
Authors: Denise A B Smith; Sampada S Vaidya; Jonathan A Kopechek; Shao-Ling Huang; Melvin E Klegerman; David D McPherson; Christy K Holland Journal: Ultrasound Med Biol Date: 2010-01 Impact factor: 2.998
Authors: Stephanie M Herbst; Melvin E Klegerman; Hyunggun Kim; Jiangbo Qi; Harnath Shelat; Michael Wassler; Melanie R Moody; Chen-Min Yang; Xinyi Ge; Yuejiao Zou; Jonathan A Kopechek; Fred J Clubb; Duane C Kraemer; Shaoling Huang; Christy K Holland; David D McPherson; Yong-Jian Geng Journal: Mol Pharm Date: 2010-02-01 Impact factor: 4.939
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: J T Sutton; K J Haworth; S K Shanmukhappa; M R Moody; M E Klegerman; J K Griffin; D M Patton; D D McPherson; C K Holland Journal: Drug Deliv Date: 2016-09-30 Impact factor: 6.419